The “everyday millionaire” population is exploding, and the rich added a record haul themselves this year. But where do they ...

Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The case, which also accused the school district of violating the Texas Open Meetings Act, was dismissed in August.